ALB and cardiovascular disorder: The use of these agents for a period of 2–4 years did not show any effects on the primary endpoint, that is normalizing the albumin‐to‐creatinine ratio over time [34], chosen as a proxy for risk of cardiovascular disease and preterm death [23].